Details of 6 Studies of Medication and Placebo for Depressed Outparticipants (Table 1 of Fournier et al., 2010).

Abbreviations: F–ITT, full intent to treat; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; Minor, minor depressive disorder; M–ITT, modified intent to treat.
aThe Barrett et al. [25] trial also included participants diagnosed with dysthymia. These participants were not included in the current analysis.
bThe Elkin et al. [26], DeRubeis et al. [27], and Wichers et al. [28] trials required participants to meet inclusion criteria in each of 2 consecutive evaluations that were held at least 1 week apart.
cThe Philipp et al. [29] trial also included a Hypericum extract condition. Data from this condition were not included in the current analyses.
d“Yes” indicates that independent blind evaluators conducted evaluations of symptom severity at every assessment. “Partial” indicates that evaluations were conducted at each session by the treating pharmacotherapists. Treating phamacotherapists were blind to treatment condition.
eSix participants from the Elkin et al. [26] sample registered scores less than 14 on the HDRS at intake (2 from the imipramine and 4 from the placebo conditions) and 1 participant from the DeRubeis et al. [27] trial registered a score less than 20 (in the paroxetine condition). These participants were retained in the present analyses.
fThe Barrett et al. [25] and DeRubeis et al. [27] studies used a full intent-to-treat design whereby all participants randomized to treatment were included in the analysis. The Dimidjian et al. [30], Elkin et al. [26], and Philipp et al. [29] studies used a modified intent-to-treat approach whereby data from only those participants who attended at least 1 treatment session or who had 1 postbaseline score were included. The Wichers et al. [28] trial included only those participants who met minimum compliance requirements for a protocol from a related research question (this sample did include treatment dropouts).
gTreatment in the Elkin et al. [26] trial was provided for 16 weeks. Because target doses were reached by the 8-week assessment, only data through week 8 were analyzed to improve comparability between the studies.
Details of 6 Studies of Medication and Placebo for Depressed Outparticipants (Table 1 of Fournier et al., 2010).